{
    "2020-08-10": [
        [
            {
                "time": "",
                "original_text": "研发日报丨百奥泰阿达木单抗获批治疗非感染性葡萄膜炎",
                "features": {
                    "keywords": [
                        "百奥泰",
                        "阿达木单抗",
                        "非感染性葡萄膜炎",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "研发日报丨贝达药业ALK抑制剂NSCLC三期临床达主要终点",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "ALK抑制剂",
                        "NSCLC",
                        "三期临床",
                        "主要终点"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "肿瘤治疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：中报窗口期继续看好业绩高增长板块 持续推荐有实力能兑现的疫苗公司",
                "features": {
                    "keywords": [
                        "医药生物",
                        "中报",
                        "高增长",
                        "疫苗公司"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "优于Xalkori！贝达药业ALK抑制剂NSCLC三期临床达主要终点",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "ALK抑制剂",
                        "NSCLC",
                        "Xalkori",
                        "三期临床"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "肿瘤治疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "时代医药周报 | 武汉出台重点监控目录，辅助用药限量降价大势所趋",
                "features": {
                    "keywords": [
                        "武汉",
                        "重点监控",
                        "辅助用药",
                        "限量降价"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "政策影响"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "A股异动丨贝达药业(300558.SZ)涨4.44%盐酸恩沙替尼eXalt3研究中期分析结果发布",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "盐酸恩沙替尼",
                        "eXalt3",
                        "研究中期分析"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "肿瘤治疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558)：恩沙一线数据靓丽 创新国际化展露头角",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "恩沙",
                        "一线数据",
                        "创新国际化"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "国际化发展"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}